MRK logo

Merck & Co., Inc. Stock Price

NYSE:MRK Community·US$286.3b Market Cap
  • 6 Narratives written by author
  • 0 Comments on narratives written by author
  • 705 Fair Values set on narratives written by author

MRK Share Price Performance

US$117.11
21.88 (22.98%)
US$210.08
Fair Value
US$117.11
21.88 (22.98%)
44.3% undervalued intrinsic discount
US$210.08
Fair Value
Price US$117.11
Vestra US$210.08

MRK Community Narratives

Vestra·
Fair Value US$210.08 44.3% undervalued intrinsic discount

"Oncology Anchor" to "Multipolar Powerhouse"

5users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
MRK logo
Merck

"Oncology Anchor" to "Multipolar Powerhouse"

In 2026, Merck has successfully dismantled the "one-trick pony" label. The story is no longer about surviving 2028, but about the compounding of a multipolar revenue engine.Read more

View narrative
481
users have viewed this narrative
5users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
US$210.08
44.3% undervalued intrinsic discount
Vestra's Fair Value
Revenue
20.4% p.a.
Profit Margin
29.63%
Future PE
14.13x
Price in 2031
US$294.01

Trending Discussion

Updated Narratives

MRK logo

"Oncology Anchor" to "Multipolar Powerhouse"

Fair Value: US$210.08 44.3% undervalued intrinsic discount
10 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued established dividend payer.

2 Risks
5 Rewards

Merck & Co., Inc. Key Details

US$65.0b

Revenue

US$14.8b

Cost of Revenue

US$50.2b

Gross Profit

US$31.9b

Other Expenses

US$18.3b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 30, 2026
7.38
77.21%
28.08%
93.7%
View Full Analysis

About MRK

Founded
1891
Employees
74000
CEO
Robert Davis
WebsiteView website
www.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Recent MRK News & Updates

Recent updates

No updates